Short answer: in most psychedelic trials, the psychological support looks like psychotherapy rather than just a safety procedure, although it also serves safety functions.
A recent systematic review assessed clinical trials with psilocybin, MDMA, or LSD against a 4-item common factors framework and reported that 69% of 29 included trials met all psychotherapy criteria, with 84% among studies that labeled their approach as psychotherapy and 40% even when not labeled as such. You can read the abstract here: PubMed.
This review focuses on how support is delivered, not on which approach improves outcomes. The authors argue that recognizing the support as psychotherapy has implications for regulation, clinician training, session duration, and transparent reporting. For future research, clearer definitions and comparator arms with minimal or non-psychotherapeutic support could help disentangle drug effects from therapy effects, while maintaining ethical safeguards.
In short, most support in psychedelic trials qualifies as psychotherapy, with safety as an important but not exclusive role.